Literature DB >> 24793496

miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2.

Tong Li1, Jue Yang, Xiaobo Lv, Kunmei Liu, Chao Gao, Yingying Xing, Tao Xi.   

Abstract

MicroRNAs play important roles in carcinogenesis by negatively regulating the expression of target genes. Here we explore the biological function of miR-155 and the underlying mechanism in colorectal carcinoma. We validate, for the first time, that E2F2 is a direct target of miR-155 using western blot and a luciferase reporter assay and that miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2 using siRNA technology. We also found, for the first, time that E2F2 acts as a tumor suppressor in colorectal carcinoma. Overall, miR-155 plays an important role in colorectal carcinoma tumorigenesis by negative regulation of its targets including E2F2 and may be a potential therapeutic target for colorectal carcinoma treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24793496     DOI: 10.1007/s10529-014-1540-3

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  25 in total

Review 1.  Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Authors:  Akira Kurozumi; Yusuke Goto; Atsushi Okato; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

2.  Characterization of miR-146a and miR-155 in blood, tissue and cell lines of head and neck squamous cell carcinoma patients and their impact on cell proliferation and migration.

Authors:  Cornelia Lerner; Silke Wemmert; Florian Bochen; Philipp Kulas; Maximilian Linxweiler; Andrea Hasenfus; Joana Heinzelmann; Petra Leidinger; Christina Backes; Eckart Meese; Steffi Urbschat; Bernhard Schick
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-30       Impact factor: 4.553

3.  Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer.

Authors:  Zhong-chuan Lv; Yong-sheng Fan; Hong-bing Chen; Da-wei Zhao
Journal:  Tumour Biol       Date:  2014-12-21

4.  Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells.

Authors:  Lixia Lv; Xiumei An; Hongyan Li; Lanxiu Ma
Journal:  Oncol Lett       Date:  2015-12-03       Impact factor: 2.967

5.  Protective Role of lncRNA TTN-AS1 in Sepsis-Induced Myocardial Injury Via miR-29a/E2F2 Axis.

Authors:  Xinghua Pei; Yanhong Wu; Haiming Yu; Yuji Li; Xu Zhou; Yanjun Lei; Wu Lu
Journal:  Cardiovasc Drugs Ther       Date:  2021-09-14       Impact factor: 3.727

Review 6.  Small molecules targeting microRNA for cancer therapy: Promises and obstacles.

Authors:  Di Wen; Michael Danquah; Amit Kumar Chaudhary; Ram I Mahato
Journal:  J Control Release       Date:  2015-08-06       Impact factor: 9.776

7.  Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2.

Authors:  Yuan-Xue Jiang; Zi-Ming Du; Lin Jiao; Qiong Shao; Sha Fu; Jian-Yong Shao; Xiao-Feng Zhu; Ingemar Ernberg; Yu-Hong Li
Journal:  Int J Clin Exp Med       Date:  2015-06-15

8.  A lncRNA TCL6-miR-155 Interaction Regulates the Src-Akt-EMT Network to Mediate Kidney Cancer Progression and Metastasis.

Authors:  Priyanka Kulkarni; Pritha Dasgupta; Yutaka Hashimoto; Marisa Shiina; Varahram Shahryari; Z Laura Tabatabai; Soichiro Yamamura; Yuichiro Tanaka; Sharanjot Saini; Rajvir Dahiya; Shahana Majid
Journal:  Cancer Res       Date:  2021-01-26       Impact factor: 13.312

Review 9.  MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer.

Authors:  Jian Wang; Yong Du; Xiaoming Liu; William C Cho; Yinxue Yang
Journal:  Biomed Res Int       Date:  2015-05-06       Impact factor: 3.411

10.  Tripartite containing motif 32 modulates proliferation of human neural precursor cells in HIV-1 neurodegeneration.

Authors:  M Fatima; R Kumari; J C Schwamborn; A Mahadevan; S K Shankar; R Raja; P Seth
Journal:  Cell Death Differ       Date:  2015-11-20       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.